FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches
RSC Advances · 2026 · 16 (35) · 34884-34965
DOI: 10.1039/d6ra01319h ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Fatma M Elmenier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt fatma.mohamed.ahmed@pharma.asu.edu.eg khale…. Die Arbeit nennt 460 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
To overcome FLT3 mutations, especially ITD, this review highlights dual inhibitors targeting multiple pathways simultaneously and irreversible inhibitors ensuring permanent FLT3 inhibition, alongside effective PROTACs and combination therapies.
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt fatma.mohamed.ahmed@pharma.asu.edu.eg khaled.abouzid@pharma.asu.edu.eg dalal@pharma.asu.edu.eg.
ORCID-Profile: Fatma M Elmenier, Eman M E Dokla, Nermin Samir, Deena S Lasheen, Khaled A M Abouzid, Dalal A Abou El Ella
Zitieren
APA
Elmenier, F. M., Dokla, E. M. E., Samir, N., Lasheen, D. S., Abouzid, K. A. M., & Abou El Ella, D. A. (2026). FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches. RSC Advances, 16(35), 34884-34965. https://doi.org/10.1039/d6ra01319h
Vancouver
Elmenier FM, Dokla EME, Samir N, Lasheen DS, Abouzid KAM, Abou El Ella DA. FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches. RSC Advances. 2026;16(35):34884-34965. doi:10.1039/d6ra01319h
BibTeX
@article{Elmenier2026,
author = {Elmenier, Fatma M and Dokla, Eman M E and Samir, Nermin and Lasheen, Deena S and Abouzid, Khaled A M and Abou El Ella, Dalal A},
title = {FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {35},
pages = {34884--34965},
doi = {10.1039/d6ra01319h}
}
EUVIMED